These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35666557)

  • 1. Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores.
    Wu Y; Yang X; Morris HL; Gurka MJ; Shenkman EA; Cusi K; Bril F; Donahoo WT
    JMIR Med Inform; 2022 Jun; 10(6):e36997. PubMed ID: 35666557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 3. FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.
    De A; Keisham A; Mishra S; Mehta M; Verma N; Premkumar M; Taneja S; Das A; Singh V; Duseja A
    J Clin Exp Hepatol; 2022; 12(2):440-447. PubMed ID: 35535068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Machine Learning Method to Identify the Risk Factors for Liver Fibrosis Progression in Nonalcoholic Steatohepatitis.
    Suárez M; Martínez R; Torres AM; Torres B; Mateo J
    Dig Dis Sci; 2023 Sep; 68(9):3801-3809. PubMed ID: 37477764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
    Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S
    J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
    Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.
    Angulo P; Bugianesi E; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Barrera F; Haflidadottir S; Day CP; George J
    Gastroenterology; 2013 Oct; 145(4):782-9.e4. PubMed ID: 23860502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis.
    Ismaiel A; Leucuta DC; Popa SL; Fagoonee S; Pellicano R; Abenavoli L; Dumitrascu DL
    Panminerva Med; 2021 Dec; 63(4):508-518. PubMed ID: 33165307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.